Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020097609 - GPR139 RECEPTOR MODULATORS

Publication Number WO/2020/097609
Publication Date 14.05.2020
International Application No. PCT/US2019/060788
International Filing Date 11.11.2019
IPC
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61K 31/4196 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41961,2,4-Triazoles
CPC
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • BLACKTHORN THERAPEUTICS, INC. [US]/[US]
Inventors
  • JONES, Robert M.
  • BRANDT, Gary
Agents
  • COOPER, Michael, P.
  • OBEIDAT, Baha, A.
  • KUMABE, Blake, K.
  • SOLTANI, Bobby, B.
  • ZENTZ, Bradley, J.
  • SARGEANT, Brooke
  • QUIST, Brooke, W.
  • ROTH, Carol, J.
  • EIDT, Chandra, E.
  • WITTKOPP, Cristina, J.
  • O'BRIEN, Daniel
  • CARLSON, David, V.
  • STARK, Duncan
  • TARLETON, E., Russell
  • SUN, Eileen, S.
  • HARWOOD, Eric, A.
  • GERTZ, Glenda, A.
  • HAN, Hai
  • TALBERT, Hayley, J.
  • BARRETT, Jared, M.
  • MIXCO, Javier, M.
  • SAKOI, Jeffrey, M.
  • BAUNACH, Jeremiah, J.
  • ZHANG, Jianping
  • MORGAN, John, A.
  • WAKELEY, John, J.
  • COE, Justin, E.
  • HENCKEL, Karen, M.
  • HEFTER, Karl, A.
  • HERMANNS, Karl, R.
  • CLAYTON, Kenneth, W.
  • MORGAN, Kevan, L.
  • COSTANZA, Kevin, S.
  • RUSYN, Paul
  • LIN, Qing
  • HALLER, Rachel, A.
  • IANNUCCI, Robert
  • WEBB, Samuel, E.
  • LIU, Shi
  • LEEK, Shoko, I.
  • ROSENMAN, Stephen, J.
  • LAWRENZ, Steven, D.
  • ABEDI, Syed
  • BOLLER, Timothy, L.
  • LIGON, Toby, J.
  • SHEWMAKE, Thomas, A.
  • CANTRELL, Tyler, C.
  • SAKOI, Zachary, M.
Priority Data
62/758,44509.11.2018US
62/758,45109.11.2018US
62/760,83913.11.2018US
62/760,84113.11.2018US
62/760,84713.11.2018US
62/760,84913.11.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) GPR139 RECEPTOR MODULATORS
(FR) MODULATEURS DU RÉCEPTEUR GPR139
Abstract
(EN)
Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (X) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R2, R3, R4, R9, R10, R11, and R12, Q5, Q6, Q7 and Q8 are as defined herein.
(FR)
L'invention concerne des composés qui modulent le récepteur GPR139, des compositions les contenant, et leurs procédés de préparation et d'utilisation pour le traitement d'une maladie dans laquelle la modulation du récepteur GPR139 est indiquée ou bénéfique du point de vue médical. De tels composés ont la structure de formule (X) ou un isomère, racémate, hydrate, solvate, isotope, ou sel pharmaceutiquement acceptable de ceux-ci, R1, R2, R3, R4, R9, R10, R11 et R12, Q5, Q6, Q7 et Q8 étant tels que définis dans la description.
Latest bibliographic data on file with the International Bureau